NEW YORK (GenomeWeb News) – Diagnostics developer Asuragen said today that is has received accreditation as a CLIA-compliant lab by the College of American Pathologists (CAP).

The Austin, Texas-based firm said that the CAP accreditation is "a crucial step" in its plans to begin commercializing its miRNA-based oncology and clinical sample testing services.